clinical trial · NCT05265325
A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis
Renal AnemiaAND017 capsules TIWAND017 capsules QWepoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars
brief summary
This is a phase II study to evaluate the safety and efficacy of AND017 in renal anemia patients on dialysis
started
May 3, 2023
primary completion
Feb 29, 2024
completion
Apr 25, 2024
last updated
Jun 28, 2024
detailed description
This is a Phase II study to assess the safety and efficacy of AND017 in patients with CKD who are anemic and on dialysis.
official title
A Phase 2, Multicenter, Open-label, Randomized, Active-Controlled Study of Efficacy and Safety of AND017 in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol